A Dark Vector Cognition product

Merck & Co. 10-Q 2026-09-30

MRK · CIK 310158 · Form 10-Q · Period ended September 30, 2026 · Filed November 4, 2026

Revenue rose 4.7% to $18.1 billion. Net income was $5.07 billion.

7 sections, 310K characters. Original on sec.gov · ·

Business

Key numbers
MeasureQuarter ended Sep 30, 2026Quarter ended Sep 30, 2025Change
Revenue$18.1B$17.3B+4.7%
Net income$5.07B$5.79B-12.4%
Diluted EPS$2.04$2.32-12.1%
Cash and equivalents$9.55Bn/an/a

From the XBRL facts tagged to this filing; both columns are as reported in this filing.

The 61 tables in this filing as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

Cover and table of contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2026

OR

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______ to ______

Commission File No. 1-6571

Merck & Co., Inc.

(Exact name of registrant as specified in its charter)

New Jersey22-1918501
(State or other jurisdiction of incorporation)(I.R.S. Employer Identification No.)
126 East Lincoln Avenue
RahwayNew Jersey07065
(Address of principal executive offices) (zip code)

(Registrant’s telephone number, including area code) (908) 740-4000

Not Applicable
(Former name, former address and former fiscal year, if changed since last report.)
Securities Registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock ($0.50 par value)MRKNew York Stock Exchange
3.250% Notes due 2032MRK/32New York Stock Exchange
2.500% Notes due 2034MRK/34New York Stock Exchange
1.375% Notes due 2036MRK 36ANew York Stock Exchange
3.500% Notes due 2037MRK/37New York Stock Exchange
3.700% Notes due 2044MRK/44New York Stock Exchange
3.750% Notes due 2054MRK/54New York Stock Exchange

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.

Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of common stock outstanding as of the close of business on October 31, 2026: 2,465,245,688

Table of Contents

Page No.
PART IFINANCIAL INFORMATION3
Item 1.Financial Statements3
Condensed Consolidated Statement of Operations3
Condensed Consolidated Statement of Comprehensive Income (Loss)3
Condensed Consolidated Balance Sheet4
Condensed Consolidated Statement of Cash Flows5
Notes to Condensed Consolidated Financial Statements6
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations32
Item 3.Quantitative and Qualitative Disclosures about Market Risk47
Item 4.Controls and Procedures47
Cautionary Factors That May Affect Future Results47
PART IIOTHER INFORMATION48
Item 1.Legal Proceedings48
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds48
Item 5.Other Information48
Item 6.Exhibits49
Signatures50

Part I - Financial Information

Item 1. Financial Statements

MERCK & CO., INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

(Unaudited, $ in millions except per share amounts)

Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Sales$18,085$17,276$50,978$48,611
Costs, Expenses and Other
Cost of sales4,8923,85513,48210,831
Selling, general and administrative2,8862,6338,4917,835
Research and development4,5374,23426,87111,903
Restructuring costs18447530676
Other (income) expense, net27(238)262(281)
12,52610,53149,63630,964
Income Before Taxes5,5596,7451,34217,647
Income Tax Provision4929581,8552,346
Net Income (Loss)5,0675,787(513)15,301
Less: Net Income (Loss) Attributable to Noncontrolling Interests22(3)10
Net Income (Loss) Attributable to Merck & Co., Inc.$5,065$5,785$(510)$15,291
Basic Earnings (Loss) per Common Share Attributable to Merck & Co., Inc. Common Shareholders$2.05$2.32$(0.21)$6.09
Earnings (Loss) per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders$2.04$2.32$(0.21)$6.08

MERCK & CO., INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (LOSS)

(Unaudited, $ in millions)

Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Net Income (Loss) Attributable to Merck & Co., Inc.$5,065$5,785$(510)$15,291
Other Comprehensive Income (Loss) Net of Taxes:
Net unrealized (loss) gain on derivatives, net of reclassifications(47)170244(457)
Benefit plan net gain and prior service credit, net of amortization70748348
Cumulative translation adjustment31(25)72152
54219399(257)
Comprehensive Income (Loss) Attributable to Merck & Co., Inc.$5,119$6,004$(111)$15,034

The accompanying notes are an integral part of these condensed consolidated financial statements.

- 3 -

MERCK & CO., INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEET

(Unaudited, $ in millions except per share amounts)

September 30, 2026December 31, 2025
Assets
Current Assets
Cash and cash equivalents$9,550$14,565
Short-term investments100—
Accounts receivable (net of allowance for doubtful accounts of $108 in 2026 and $97 in 2025)12,74411,775
Inventories (excludes inventories of $6,341 in 2026 and $5,681 in 2025 classified in Other assets - see Note 6)6,1646,658
Other current assets10,38310,518
Total current assets38,94143,516
Investments1,603956
Property, Plant and Equipment, at cost, net of accumulated depreciation of $22,402 in 2026 and $21,914 in 202525,90425,316
Goodwill21,95121,579
Other Intangibles, Net24,47626,681
Other Assets19,89818,818
$132,773$136,866
Liabilities and Equity
Current Liabilities
Loans payable and current portion of long-term debt$4,088$2,589
Trade accounts payable5,0314,404
Accrued and other current liabilities13,23914,468
Income taxes payable4,3094,726
Dividends payable2,1342,140
Total current liabilities28,80128,327
Long-Term Debt49,68946,750
Deferred Income Taxes1,4601,439
Other Noncurrent Liabilities7,8777,688
Merck & Co., Inc. Stockholders’ Equity
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2026 and 20251,7881,788
Other paid-in capital45,36245,029
Retained earnings66,22373,075
Accumulated other comprehensive loss(3,888)(4,287)
109,485115,605
Less treasury stock, at cost: 1,110,329,221 shares in 2026 and 1,102,476,756 shares in 202564,59262,999
Total Merck & Co., Inc. stockholders’ equity44,89352,606
Noncontrolling Interests5356
Total equity44,94652,662
$132,773$136,866

The accompanying notes are an integral part of this condensed consolidated financial statement.

- 4 -

MERCK & CO., INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(Unaudited, $ in millions)

Nine Months Ended September 30,
20262025
Cash Flows from Operating Activities
Net (loss) income$(513)$15,301
Adjustments to reconcile net (loss) income to net cash provided by

Showing the first 8K of 191K characters. Open the full section

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Business Development Transactions

Below is a summary of significant business development activity thus far in 2026.

In September 2026, Merck and SciBrunch Therapeutics Co., Ltd. (SciBrunch) closed an exclusive license agreement for MK-2690 (SPR2015), a potent and selective novel, investigational, preclinical, molecular glue KRAS G12D (ON) inhibitor, targeting cancers and tumors characterized by the KRAS G12D mutation. Under the agreement, SciBrunch granted Merck exclusive rights to develop, manufacture and commercialize MK-2690 (SPR2015) worldwide. The Company recorded a charge to Research and development expenses of $400 million in the third quarter and first nine months of 2026, or $0.12 per share, for the upfront payment, which is expected to be paid in the fourth quarter of 2026. SciBrunch is also eligible to receive future contingent development-related, regulatory, and, if approved, sales-based milestone payments.

In July 2026, Merck acquired TARGAN, a privately held company developing and commercializing biodevice solutions to improve performance outcomes for the poultry industry, for $647 million. The acquisition will broaden Merck Animal Health’s portfolio in commercial poultry operations with WingScan, an automated solution that uses vision technology for gender identification. This acquisition also brings the capability for a high-speed precision ocular spray technology, which administers respiratory and coccidiosis vaccines, among others, to day-old chicks. In addition, TARGAN has the potential to develop additional biodevices within poultry and other livestock species. Merck recorded a realized gain of $68 million to Other (income) expense, net in the first nine months of 2026 related to an existing investment that Merck held in TARGAN. The transaction was accounted for as a business combination. There are no future contingent payments associated with the acquisition.

In May 2026, Merck acquired Terns Pharmaceuticals, Inc. (Terns), a clinical-stage oncology company, for $6.8 billion (including $606 million of payments to settle share-based equity awards of which $433 million related to unvested equity awards). Through this acquisition, Merck acquired Terns’ lead candidate, MK-4208 (formerly TERN-701), a novel investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor (TKI) currently being evaluated in a Phase 1/2 trial for patients with Philadelphia chromosome-positive, chronic phase chronic myeloid leukemia previously treated with at least one prior TKI and who experienced treatment failure, suboptimal response or treatment intolerance. The transaction was accounted for as an asset acquisition because MK-4208 accounted for substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded a charge of $5.7 billion to Research and development expenses (which primarily represented acquired in-process research and development [IPR&D] with no alternative future use), or $2.31 per share, in the first nine months of 2026, as well as net assets of $1.1 billion, including cash of $505 million, investments of $487 million, deferred tax assets of $190 million, and other net liabilities of $105 million. There are no future contingent payments associated with the acquisition.

In January 2026, Merck acquired Cidara Therapeutics, Inc. (Cidara), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, for $9.2 billion (including $570 million of payments to settle share-based equity awards of which $406 million related to unvested equity awards). Cidara’s lead DFC candidate, MK-1406 (formerly CD388), is a long-acting antiviral designed to prevent seasonal and pandemic influenza. MK-1406 is currently being evaluated in a Phase 3 trial among adult and adolescent participants who are at higher risk of developing complications from influenza. The transaction was accounted for as an asset acquisition because MK-1406 accounted for substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded a charge of $9.0 billion to Research and development expenses (which primarily represented acquired IPR&D with no alternative future use), or $3.62 per share, in the first nine months of 2026, as well as net assets of $332 million. Under a previous license agreement between Cidara and J&J Innovative Medicine (a Johnson & Johnson company, previously Janssen Pharmaceuticals, Inc.), which was assumed by Merck, J&J Innovative Medicine is eligible to receive regulatory and sales-based milestones related to MK-1406.

Pricing

Global efforts toward health care cost containment continue to exert pressure on product pricing and market access worldwide. Changes to the U.S. health care system as part of health care reform, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure.

In 2021, the U.S. Congress passed the American Rescue Plan Act, which included a provision that eliminated the statutory cap on rebates drug manufacturers pay to Medicaid beginning in January 2024.

In 2022, the U.S. Congress passed the Inflation Reduction Act (IRA), which made significant changes to how drugs are covered and paid for under the Medicare program, including the creation of financial penalties for drugs whose prices rise faster than the rate of inflation, redesign of the Medicare Part D program to require manufacturers to bear more of the liability for certain drug benefits (which went into effect in 2025), and government price-setting for certain Medicare Part D drugs (which went into effect in 2026) and Medicare Part B drugs (starting in 2028). The U.S. Department of Health and Human Services (HHS), through the Centers for Medicare & Medicaid Services (CMS), selected Januvia (sitagliptin) in 2023 for the first year of the IRA’s “Drug Price Negotiation Program” (Program), and selected Janumet (sitagliptin and metformin HCl) and Janumet XR (sitagliptin and metformin HCl extended release) in 2025 for the second year of the IRA’s Program. Pursuant to the IRA’s Program, the government set a price for Januvia, which became effective on January 1, 2026, and set a price for Janumet and Janumet XR, which will become effective on January 1, 2027. In addition, in January 2026, HHS announced that Lenvima (lenvatinib) has been selected for government price setting, the set price for which will become effective on January 1, 2028. Furthermore, the Company expects that Keytruda (pembrolizumab) will be selected in 2027 for government price setting, which

- 32 -

would become effective on January 1, 2029; a pending CMS proposed rule may subject Keytruda Qlex (pembrolizumab and berahyaluronidase alfa) to price setting at the same time. Government price setting may also impact pricing in the private market negatively affecting the Company’s performance.

Additionally, increased utilization of the 340B Federal Drug Discount Program and restrictions on the Company’s ability to identify inappropriate discounts are having a negative impact on Company performance. Furthermore, the Executive Branch and Congress continue to discuss legislation designed to control health care costs, including the cost of drugs.

In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Company’s sales performance in the first nine months of 2026 was negatively affected by other cost-reduction measures taken by governments and other third parties to lower health care costs. In July 2026, the German parliament approved the Statutory Health Insurance Contribution Rate Stabilization Act (GKV-BStabG), a comprehensive health care reform law designed to reduce health insurance expenditures. The legislation introduces significant cost-containment measures that directly

Showing the first 8K of 103K characters. Open the full section

Item 3. Quantitative and Qualitative Disclosures about Market Risk

There have been no material changes in market risk exposures that affect the disclosures presented in “Item 7A. Quantitative and Qualitative Disclosures about Market Risk” in the Company’s 2025 Form 10-K filed on February 24, 2026.

Item 4. Controls and Procedures

Management of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures over financial reporting. Based on their evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that as of September 30, 2026, the Company’s disclosure controls and procedures are effective. For the third quarter of 2026, there were no changes in internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS

This report and other written reports and oral statements made from time to time by the Company may contain so-called “forward-looking statements,” all of which are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially from those set forth in the statements. One can identify these forward-looking statements by their use of words such as “anticipates,” “expects,” “plans,” “will,” “estimates,” “forecasts,” “projects” and other words of similar meaning, or negative variations of any of the foregoing. One can also identify them by the fact that they do not relate strictly to historical or current facts. These statements are likely to address the Company’s growth strategy, financial results, product approvals, product potential, or development programs. One must carefully consider any such statement and should understand that many factors could cause actual results to differ materially from the Company’s forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks and uncertainties, including some

- 47 -

that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially.

The Company does not assume the obligation to update any forward-looking statement. One should carefully evaluate such statements in light of factors, including risk factors, described in the Company’s filings with the Securities and Exchange Commission, especially on Forms 10-K, 10-Q and 8-K. In Item 1A. “Risk Factors” of the Company’s Annual Report on Form 10‑K for the year ended December 31, 2025, filed on February 24, 2026, the Company discusses in more detail various important risk factors that could cause actual results to differ from expected or historic results. The Company notes these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. One should understand that it is not possible to predict or identify all such factors. Consequently, the reader should not consider any such list to be a complete statement of all potential risks or uncertainties.

PART II - Other Information

Item 1. Legal Proceedings

The information called for by this Item is incorporated herein by reference to Note 8 included in Part I, Item 1, Financial Statements (unaudited) — Notes to Condensed Consolidated Financial Statements.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Issuer purchases of equity securities for the three months ended September 30, 2026 were as follows:

ISSUER PURCHASES OF EQUITY SECURITIES

($ in millions)
PeriodTotal Number of Shares Purchased (1)Average Price Paid Per ShareTotal Number of Shares Purchased as Part of Publicly Announced Plans or ProgramsApproximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs (1)
July 1 - July 311,816,435$127.191,816,435$5,505
August 1 - August 311,549,400$138.241,549,400$5,291
September 1 - September 301,411,750$147.801,411,750$5,082
Total4,777,585$136.864,777,585

(1) Shares purchased during the period were made as part of a plan approved by the Board of Directors in January 2025 to purchase up to $10 billion of Merck’s common stock for its treasury.

Item 5. Other Information

Insider Trading Arrangements

During the three months ended September 30, 2026, none of the Company’s directors or executive officers adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each item is defined in Item 408 of Regulation S-K.

- 48 -

Item 6. Exhibits

NumberDescription
3.1—Restated Certificate of Incorporation of Merck & Co., Inc. (November 3, 2009) – Incorporated by reference to Merck & Co., Inc.'s Current Report on Form 8-K filed on November 4, 2009 (No. 1-6571)
3.2—By-Laws of Merck & Co., Inc. (effective November 19. 2024) – Incorporated by reference to Merck & Co., Inc.'s Current Report on Form 8-K filed on November 22, 2024 (No. 1-6571)
31.1—Rule 13a – 14(a)/15d – 14(a) Certification of Chief Executive Officer
31.2—Rule 13a – 14(a)/15d – 14(a) Certification of Chief Financial Officer
32.1—Section 1350 Certification of Chief Executive Officer
32.2—Section 1350 Certification of Chief Financial Officer
101.INS—XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.
101.SCH—XBRL Taxonomy Extension Schema Document.
101.CAL—XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF—XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB—XBRL Taxonomy Extension Label Linkbase Document.
101.PRE—XBRL Taxonomy Extension Presentation Linkbase Document.
104—Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

- 49 -

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MERCK & CO., INC.
Date: November 4, 2026/s/ Jennifer Zachary
JENNIFER ZACHARY
Executive Vice President and General Counsel
Date: November 4, 2026/s/ Dalton Smart
DALTON SMART
Senior Vice President Finance - Global Controller

- 50 -